Get started
Tiziana Life Sciences LtdTiziana Life Sciences LtdTiziana Life Sciences Ltd

Tiziana Life Sciences Ltd

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Options

TLSA trade ideas

Tiziana (NASDAQ: TLSA) is Setting Up for a Major Move Today!Tiziana Life Sciences Ltd (NASDAQ: TLSA) has been gaining traction following our initial alert! The stock has been steadily climbing, closing Friday’s session at $0.792, up 7.03%, with volume surging from $184,039 to $346,792. Market cap has also surged from a low of $81.23M to $86.40M, signaling growing investor confidence. With momentum steadily building and market interest growing, we anticipate further upside as the new trading week begins. TLSA continues to push forward in the biotech space, this could be a pivotal moment for the stock. With a pipeline of cutting-edge therapies targeting some of the most challenging diseases, NASDAQ: TLSA could be on the verge of a game-changing breakout. Technical Outlook: TLSA continues to showcase bullish momentum, backed by strong trading volume and key technical patterns. The double-bottom formation at the $0.63 range remains intact, historically a pattern associated with significant breakouts. Additionally, with RSI at 56.84 and trading below its moving average, there’s ample room for further upside. An 85% surge remains a viable target. TLSA’s Breakthrough in Immunotherapy TLSA stands out due to its groundbreaking work in immunology and oncology, particularly in developing next-generation immunotherapies for neurodegenerative diseases. With its lead candidate, Foralumab (TZLS-401), targeting Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s, and ALS, the company is positioned for major breakthroughs in the biotech space. Moreover, the company has filed a patent application for Foralumab’s potential use in enhancing CAR-T cell therapy, a move that could revolutionize cancer treatment. With a lean operational model maximizing value, TLSA remains a compelling buy.
NASDAQ:TLSA
by DEXWireNews
2
$TLSA Poised For An 85% Surge Amidst Alzheimer’s Drug BoomTiziana Life Sciences Ltd (NASDAQ: NASDAQ:TLSA ), a stock that has been under the radar, is now showing strong signals of a potential breakout. With a falling wedge pattern and a bullish RSI reading, coupled with the growing interest in Alzheimer’s drug development, NASDAQ:TLSA is positioning itself as a stock to watch in 2025. Technical Analysis As of the time of writing, (NASDAQ: NASDAQ:TLSA ) shares are down 5.52%, but this dip is likely a temporary setback. The stock’s Relative Strength Index (RSI) stands at 52.77, which, despite the recent decline, suggests that bullish momentum is building. The RSI is neither overbought nor oversold, indicating a healthy consolidation phase before a potential upward move. The most Intriguing technical indicator is the falling wedge pattern that has formed since January 23. This pattern is typically a bullish reversal signal, especially after a prolonged downtrend. The falling wedge is characterized by converging trendlines that slope downward, with the price making lower highs and lower lows. As the pattern nears its apex, the likelihood of a breakout increases. For NASDAQ:TLSA , the immediate support lies at the 78.6% Fibonacci retracement level. A pullback to this zone could serve as an excellent buying opportunity for traders, as it aligns with recent resistance-turned-support levels. On the upside, the 38.2% Fibonacci retracement level is acting as a pivot point. A breakout above this level could ignite a bullish rally, potentially propelling the stock toward an 85% surge. Alzheimer’s Drugs – The Next Big Market Opportunity While the technical setup is compelling, the story behind NASDAQ:TLSA is equally intriguing. The Alzheimer’s drug market is emerging as the next big opportunity, drawing parallels to the obesity drug boom led by companies like Eli Lilly and Novo Nordisk. With an estimated market value of $13 billion by 2030, according to Bloomberg Intelligence, the race to develop effective Alzheimer’s treatments is heating up. Companies like Biogen Inc., Eli Lilly & Co., Novo Nordisk, and Roche AG are investing billions into Alzheimer’s research. Recent developments have shown promise, with two new drugs—Leqembi (developed by Biogen and Eisai) and Kisunla (by Eli Lilly)—already approved in the U.S. These drugs target amyloid plaques in the brain, slowing the progression of the disease in its early stages. However, they are not without challenges, as side effects like brain bleeding and swelling have been reported. For (NASDAQ: NASDAQ:TLSA ) stock, this presents a unique opportunity. If the company is involved in Alzheimer’s research or has partnerships with major pharmaceutical players, it could benefit significantly from the growing interest in this sector. Even if NASDAQ:TLSA is not directly involved, the overall bullish sentiment in the healthcare and biotech sectors could provide a tailwind for the stock. Additionally, any positive developments in Alzheimer’s drug trials or approvals could act as a catalyst for NASDAQ:TLSA , driving the stock higher. As Gregoire Biollaz, senior investment manager at Pictet Asset Management, noted, “It could be a year where we also see a bit more clarity in terms of traction for the drugs that are approved so far.” Conclusion NASDAQ: NASDAQ:TLSA is at a critical juncture, with both technical and fundamental indicators pointing to a potential surge. The falling wedge pattern suggest that the stock is building momentum, while the growing interest in Alzheimer’s drugs provides a strong fundamental catalyst. For investors seeking the next big opportunity, NASDAQ:TLSA could be the stock to watch in 2025. As always, investors should conduct their own due diligence and consider their risk tolerance before making any investment decisions. However, with an 85% surge on the horizon, NASDAQ:TLSA is undoubtedly a stock worth keeping on your radar.
NASDAQ:TLSALong
by DEXWireNews
$TLSA Target 3.91 for 41.67% $TLSA Target 3.91 for 41.67% Or next add level is at 1.61 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NASDAQ:TLSALong
by SPYder_QQQueen_Trading
2
$TLSA Target 4.82 for 31.34% LET'S GO$TLSA Target 4.82 for 31.34% Or next add level is at 2.52 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NASDAQ:TLSALong
by SPYder_QQQueen_Trading
1
$TLSA is gonna fall todayPupm&Dump trading strategy idea. $TLSA is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $5,65; stop-loss — $6,50; take-profit — $4,00; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:TLSAShort
by KozakHlib
TLSA - PLAYING THE WEDGE GAMEPossible entry 3.52/3.55 on a trending support hold Okay, here's a possible move play! Favorable trading and charting conditions in my opinion. Why? 1. Wedge formations can become parabolic signals. The highs and lows are trading inside this wedge. 2. This is an upwards trending stock, with the pricepoints holding, again inside this wedge. 3. The Stochastic indicator is suggesting a further move south. This indicator is a great source for stock sentiment. It is waning, but knowledge says to buy the oversold condition on an upwards moving stock, if volume and ema points are solid. In short, buying the discount. 4. The 8 EMA is the pivot line, like a fishing bobber, where price wants to stay near. The 34 EMA should not be a factor in this case. *Let's see what happens DISCLAIMER - I am not a professional trader. These are merely my thoughts and possible moves; i enjoy watching these stocks validate my process or slap me across the face lol. If you are in need of professional assistance with your trades, don't look here. I am not that guy.
NASDAQ:TLSALong
by mrmaximo74
Tiziana Life Sciences Plc Covid-19 TreatmentThinly traded nano cap Tiziana Life Sciences (NASDAQ:TLSA) is the latest coronavirus play. Shares are up 306% premarket on average volume in reaction to its announcement that candidate TZLS-501 may be a potential treatment for COVID-19 patients at risk of respiratory failure. The company says it plans to administer TZLS-501, an interleukin 6 (IL-6)-inhibiting monoclonal antibody, using a proprietary formulation technology, adding that excess production of IL-6 is a key driver of chronic inflammation and is believed to play a key role in severe lung damage seen with COVID-19 infection and acute respiratory illness. Source seekignalpha Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.
NASDAQ:TLSA
by DEXWireNews
2